Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

eye disease

  • Home
  •  
  • eye disease



  • Most Read
  • Latest Comments
  • PYC gets FDA clearance to kick off human trials for its investigative drug combatting blindness
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • PYC gets FDA clearance to kick off human trials for its investigative drug combatting blindness
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • PYC gets FDA clearance to kick off human trials for its investigative drug combatting blindness
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • PYC gets FDA clearance to kick off human trials for its investigative drug combatting blindness
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • PYC gets FDA clearance to kick off human trials for its investigative drug combatting blindness
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • PYC Therapeutics receives Orphan Drug Designation for ADOA treatment
    PYC Therapeutics receives Orphan Drug Designation for ADOA treatment
    • News

  • All eyes on PYC as it doses first patient for eye disease trial
    All eyes on PYC as it doses first patient for eye disease trial
    • News

  • PYC gets FDA clearance to kick off human trials for its investigative drug combatting blindness
    PYC gets FDA clearance to kick off human trials for its investigative drug combatting blindness
    • News

  • PYC gets FDA clearance to kick off human trials for its investigative drug combatting blindness
    • News

    PYC gets FDA clearance to kick off human trials for its investigative drug combatting blindness

    Genetic eye problems affect over two million people worldwide and often lead to blindness among the working-age population. Though there’s a lot of optimistic research into potential treatments, none exists right now. That’s what the Western Australian biotech company PYC Therapeutics (ASX: PYC) is attempting to change.  After successfully treating rabbits and monkeys suffering from

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.